ACLARIS THERAPEUTICS,INC.Files An 8-K Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders.

On June15, 2017, Aclaris Therapeutics,Inc. (the
Company)
held its 2017 annual meeting of stockholders (the
Annual
Meeting). The stockholders considered two
proposals, each of which is described in more detail in the
Companys definitive proxy statement filed with the Securities and
Exchange Commission on April21, 2017.Of the 26,098,493shares
outstanding as of the record date, 23,238,312 shares, or 89%,
were present or represented by proxy at the Annual Meeting.Set
forth below are the results of the matters submitted for a vote
of stockholders at the Annual Meeting.

Proposal No.1:Election of three nominees to
serve as directors until the 2020 annual meeting of stockholders
and until their respective successors are elected and qualified.
The votes were cast as follows:

Broker Non-Votes: 2,253,564.

All nominees were elected.

Proposal No.2:Ratification of the appointment of
PricewaterhouseCoopers LLP as independent registered public
accounting firm for the fiscal year ending December31, 2017. The
votes were cast as follows: